10:31:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-08 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-03 Split IMMU 20:1
2024-05-20 X-dag ordinarie utdelning IMMU 0.00 SEK
2024-05-17 Kvartalsrapport 2024-Q1
2024-05-17 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-12-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-15 X-dag ordinarie utdelning IMMU 0.00 SEK
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-12 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-18 Extra Bolagsstämma 2022
2022-11-11 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-11 X-dag ordinarie utdelning IMMU 0.00 SEK
2022-05-10 Kvartalsrapport 2022-Q1
2022-05-10 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-05 X-dag ordinarie utdelning IMMU 0.00 SEK
2021-05-04 Kvartalsrapport 2021-Q1
2021-05-04 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2021-01-22 Extra Bolagsstämma 2021
2020-12-18 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-04-29 X-dag ordinarie utdelning IMMU 0.00 SEK
2020-04-28 Kvartalsrapport 2020-Q1
2020-04-28 Årsstämma 2020
2020-02-18 Bokslutskommuniké 2019
2019-11-06 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-04-26 X-dag ordinarie utdelning IMMU 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-05-04 Kvartalsrapport 2018-Q1
2018-04-26 X-dag ordinarie utdelning IMMU 0.00 SEK
2018-04-25 Årsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-12-04 Extra Bolagsstämma 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-19 Kvartalsrapport 2017-Q1
2017-04-27 X-dag ordinarie utdelning IMMU 0.00 SEK
2017-04-26 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-05-20 Kvartalsrapport 2016-Q3
2016-02-19 Kvartalsrapport 2016-Q2
2015-12-03 Årsstämma 2016
2015-09-18 Bokslutskommuniké 2015
2015-05-21 Kvartalsrapport 2015-Q3
2015-02-20 Kvartalsrapport 2015-Q2
2014-12-04 X-dag ordinarie utdelning IMMU 0.00 SEK
2014-12-03 Årsstämma 2015
2014-11-18 Kvartalsrapport 2015-Q1
2014-09-17 Bokslutskommuniké 2014
2014-05-07 Kvartalsrapport 2014-Q3
2014-02-18 Kvartalsrapport 2014-Q2
2013-12-04 X-dag ordinarie utdelning IMMU 0.00 SEK
2013-12-03 Årsstämma 2014
2013-12-03 Kvartalsrapport 2014-Q1
2013-09-10 Bokslutskommuniké 2013

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Mendus är verksamt inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom området för onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av allvarliga tumörer. Exempel på sjukdomar som produkterna används mot innefattar njur- och levercancer. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget gick tidigare under namnet Immunicum och har idag sitt huvudkontor i Stockholm.
2023-02-17 08:00:00

“Mendus focuses on changing the course of cancer treatment by developing immunotherapies that combine durable clinical responses with a benign safety profile. We do so by making use of our unique expertise in allogeneic dendritic cell biology. Durability of response and safety are particularly relevant in maintenance therapies, aimed at the prevention of tumor recurrence.

The positive Phase 2 data we presented at the American Society for Hematology conference last December for our lead program DCP-001 in acute myeloid leukemia (AML) underline these principles. The data provide the basis for broader positioning and, eventually, the path to market registration of DCP-001 as a new maintenance treatment in AML. In 2022, we also reported the first positive clinical safety data with DCP-001 in ovarian cancer and completed the preparations for a next clinical trial with our intratumoral primer ilixadencel.

In January 2023, the World Health Organization (WHO) confirmed that they selected vididencel as the International Non-proprietary Name (INN) for DCP-001, and we will start using the name vididencel in our future communication. Finally, our preclinical research resulted in a novel method for the expansion of memory NK cells, potentially creating the starting point for a promising new pipeline program in the exciting upcoming field of NK cell-based therapies.

We are very happy with the progress we have made on all fronts in 2022 and the continued commitment of our entire team to develop impactful new cancer therapies. For 2023, we have taken necessary steps to focus on our most value-generating projects.”

Erik Manting, Ph.D., Chief Executive Officer of Mendus AB

 

SIGNIFICANT EVENTS IN Q4 2022

  • Mendus presented positive survival and immunomonitoring data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
  • Mendus hosted a key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
  • Mendus secured a first shareholder loan from Van Herk Investments and signs the final documentation with Negma Group
  • Mendus presented data at SITC 2022 demonstrating the potential of the DCOne platform to expand memory NK cells for therapeutic purposes
  • Mendus secured a manufacturing partner for establishing the potential pivotal trial-stage and commercial production of DCP-001
  • Mendus reported positive clinical and preclinical data in ovarian cancer at the European Society of Gynaecological Oncology 2022 Congress
  • Mendus received final payment as a result of the completion of the EU Horizon 2020 AML-VACCiN project

SIGNIFICANT EVENTS AFTER END OF REPORTING PERIOD

  • Mendus announced the request of a first tranche of the convertible loan from
    Negma Group

FINANCIAL SUMMARY

 Oct-DecOct-DecJan-DecJan-Dec
KSEK unless otherwise stated2022202120222021
Net sales
Operating profit/loss-41,557-31,746-133,957-130,100
Net profit/loss-43,280-32,843-138,786-133,410
Earnings/loss per share, before and after dilution (SEK)-0.22-0.16-0.70-0.73
Cash41,851155,31341,851155,313
Shareholders’ equity514,439656,742514,439656,742
Number of employees at the end of the period33303129

 

The Q4 2022 report is available on: https://mendus.com/investors/financial-reports/

 

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

 

INVESTOR RELATIONS

Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com

 

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu

 

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/